Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Adenoid Cystic × Epirubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 179 Triple Negative Breast Neoplasms 27 Stomach Neoplasms 27 Inflammatory Breast Neoplasms 18 Carcinoma, Hepatocellular 14 Esophageal Neoplasms 13 Lymphoma, Large B-Cell, Diffuse 8 Sarcoma 7 Neoplasms 6 Non-Muscle Invasive Bladder Neoplasms 5 Urinary Bladder Neoplasms 4 Ovarian Neoplasms 4 Testicular Neoplasms 3 Primary Breast Cancer 3 Pathologic Complete Response 3 Pancreatic Neoplasms 3 Lymphoma 3 Liver Neoplasms 3 Carcinoma, Ductal, Breast 3 Breast Neoplasms, Male 3 Adenocarcinoma Of Esophagus 3 Unspecified Adult Solid Tumor, Protocol Specific 2 Recurrence 2 Prostatic Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Osteosarcoma 2 Neoplasms, Germ Cell and Embryonal 2 Neoplasm Metastasis 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, B-Cell, Marginal Zone 2

Interventions

pembrolizumab 5 apatinib 3 Magnetic Resonance Spectroscopy 3 Imatinib Mesylate 3 Carboplatin 3 lenvatinib 2 gallium 68 PSMA-11 2 Specimen Handling 2 Nivolumab 2 Cisplatin 2 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 tislelizumab 1 regorafenib 1 enfortumab vedotin 1 cabozantinib 1 amivantamab 1 Tretinoin 1 Trastuzumab 1 Tablets 1 Standard of Care 1 Radiotherapy, Intensity-Modulated 1 Radiosurgery 1 Radiation 1 Protons 1 Pemetrexed 1 Nelfinavir 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Lutetium-177 1 Lutetium 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07320508 2026-01-21

EIC-SNACC

Eye & ENT Hospital of Fudan University

Phase 2 Recruiting

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡